Investing.com -- Piper Sandler downgraded Accolade Inc (NASDAQ:ACCD) to Neutral from Overweight and cut its price target to $7.03 per share, aligning with the proposed acquisition price in the company's pending sale to Transcarent.
Accolade agreed to be acquired by Transcarent, a healthcare navigation firm, for $7.03 per share in cash, a 110% premium to its Jan. 7 closing price.
Shareholders are set to vote on the deal at a special meeting on March 27, with closing expected in the second quarter, pending approval.
“We believe the merger terms are generally favorable and fall in line with several comparable transactions,” analyst at Piper Sandler said.
Piper Sandler noted that Accolade’s fiscal third-quarter 2025 revenue of $105.1 million slightly missed expectations, while adjusted EBITDA of negative $3.8 million came in marginally ahead. The firm also flagged downside risks to consensus estimates for fiscal years 2026-2028, based on management projections.
Despite viewing the sale process as competitive and the terms as generally favorable, Piper Sandler sees limited upside for the stock at this stage.
Related Articles
Piper Sandler downgrades Accolade ahead of shareholder vote
European steel stocks leap on German spending plans
US stocks nearly flat amid trade war worries; euro hits four-month high
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。